Coadjuvants in the Diabetic Complications: Nutraceuticals and Drugs with Pleiotropic Effects

International Journal of Molecular Sciences

Marcelo Perim Baldo¹  Marcella Lima Porto²  Silvana Santos Meyrelles³  Agata Lages Gava³  Bianca Prandi Campagnaro⁴  Fabio Silva Pimenta⁴  Thiago Melo Costa Pereira⁴  Elisardo Corral Vasquez⁴ 

[1] Department of Pathophysiology, Montes Claros State University, 39401-089, Montes Claros, Brazil;Federal Institute of Education, Science and Technology (IFES), 29106-010 Vila Velha, Brazil;Laboratory of Translational Physiology, Federal University of Espirito Santo (Ufes), 29047-100 Vitoria, Brazil;Pharmaceutical Sciences Graduate Program, Vila Velha University (UVV), Av. Comissario Jose Dantas Melo 21, Boa Vista, 29102-920 Vila Velha, Brazil;

关键词: diabetes;    quercetin;    polyphenols;    resveratrol;    silymarin;    kefir;    probiotic;    sildenafil;    phosphodiesterase inhibitors;    antioxidants;   

DOI  :  10.3390/ijms17081273

来源: DOAJ

【 摘 要 】

Because diabetes mellitus (DM) is a multifactorial metabolic disease, its prevention and treatment has been a constant challenge for basic and clinical investigators focused on translating their discoveries into clinical treatment of this complex disorder. In this review, we highlight recent experimental and clinical evidences of potential coadjuvants in the management of DM, such as polyphenols (quercetin, resveratrol and silymarin), cultured probiotic microorganisms and drugs acting through direct/indirect or pleiotropic effects on glycemic control in DM. Among several options, we highlight new promising therapeutic coadjuvants, including chemical scavengers, the probiotic kefir and the phosphodiesterase 5 inhibitors, which besides the reduction of hyperglycemia and ameliorate insulin resistance, they reduce oxidative stress and improve endothelial dysfunction in the systemic vascular circulation. In the near future, experimental studies are expected to clear the intracellular pathways involving coadjuvants. The design of clinical trials may also contribute to new strategies with coadjuvants against the harmful effects of diabetic complications.

【 授权许可】

Unknown